Narrative review / 2024
A commentary highlights potential risks of GLP-1 receptor agonists and calls for monitoring of disordered eating and maladaptive appetite responses.
Drawing on expertise in obesity medicine and psychiatry, authors reflect on the clinical use of GLP-1 receptor agonists for obesity and type 2 diabetes. They emphasize risks particularly for individuals prone to disordered eating or with rare genetic diseases of obesity. The authors argue that managing weight loss with these agents requires proactive screening for disordered eating, monitoring for maladaptive responses like food aversion and dehydration, and an interdisciplinary approach blending medical, psychological, dietary, and behavioral care.
- Study type
- Clinical commentary / perspective
- Who was studied
- Patients using GLP-1 receptor agonists for weight loss
- What was measured
- Clinical challenges, safety concerns, and monitoring recommendations
THE PAPER
Highway to the danger zone? A cautionary account that GLP-1 receptor agonists may be too effective for unmonitored weight loss.
Richards JR, Khalsa SS. Obes Rev, 2024.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.